Khaled Hassan, MD
Medical Oncology · Cleveland, OHNPI 1639291727
Payments from drug & device makers
What this record shows
This record is dominated by education: $12 of the $12 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Jazz Pharmaceuticals Inc.. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.
Across 1 payment — averaging $11.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$12
Across 33 payments — averaging $17,025 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$205K
- Daiichi Sankyo Inc.$199K
- Janssen Research & Development, LLC$85K
- E.r. Squibb & Sons, L.L.C.$33K
- Merck$26K
- Boehringer Ingelheim$14K
- plus $159 from 1 others
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 1 | $12 |
How this compares
$12 in reported general payments places this provider in the 5th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlecensaAlectinib Hcl | 42 | $736,582 |
| LumakrasSotorasib | 45 | $442,463 |
| LorbrenaLorlatinib | 12 | $253,595 |
| EliquisApixaban | 24 | $13,616 |
| XareltoRivaroxaban | 12 | $8,871 |
| Ondansetron Hcl | 74 | $1,572 |
| Olanzapine | 81 | $978 |
| Dexamethasone | 27 | $340 |
| Oxycodone Hcl | 20 | $206 |
| Levothyroxine Sodium | 30 | $169 |
| Prochlorperazine Maleate | 11 | $137 |
| Prednisone | 20 | $125 |
| Famotidine | 11 | $109 |
| Folic Acid | 18 | $76 |
| Lisinopril | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Cleveland
- Moshe OrnsteinCleveland$249K
- Suneel KamathCleveland$120K
- William TseCleveland$56K
- Amanda NizamCleveland$46K
- Melinda HsuCleveland$41K
- Jack KhouriCleveland$39K
- Jessica GeigerCleveland$33K
- Thach-Giao TruongCleveland$31K
- David PeereboomCleveland$23K
- George BuddCleveland$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.